English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background Influenza B viruses (B) co-circulate with influenza A viruses (A) and contribute to influenza-associated hospitalizations each season. We used data from the Influenza Hospitalization Surveillance Network (FluSurv-NET) to determine the association between B virus hospitalizations and mortality among children. Methods We included data from children aged 0–17 years, residing in a FluSurv-NET catchment area, and hospitalized with laboratory-confirmed influenza during 2011–2012 through 2016–2017. We abstracted data on underlying conditions, clinical course and outcomes from medical charts. After excluding cases with unknown influenza type or with A/B coinfection, we compared characteristics of children hospitalized with A vs. B using univariate analyses and multivariable logistic regression, to determine the independent association between virus type and in-hospital mortality. Results Among 7671 children hospitalized with influenza, 5607 (73%) had A and 2064 (27%) had B. The proportion of B hospitalizations varied by season from 11% during 2013–2014 to 42% during 2012–2013. Among children with B, median age was 4 years (interquartile range 1–8 years), 58% were male and 36% were non-Hispanic white. In univariate analysis, children with B were more likely to be older, have cardiovascular and neurologic disease, to be vaccinated (38 vs. 32%), and to be hospitalized ≥2 days after illness onset, and were less likely to have asthma and receive antivirals (71 vs. 79%) compared with those with A (P < 0.05). There were no differences in the proportion with ≥1 underlying condition (59% both groups). Patients with B vs. A were no more likely to require intensive care (19 vs. 20%; p 0.34) or receive mechanical ventilation (6 vs. 5%; p 0.13); however, patients with B were more likely to die in-hospital (1 vs. 0.4%; P < 0.01). The unadjusted odds of in-hospital mortality for children with B vs. A was 2.3 (95% confidence interval (CI) 1.3–4.1), which remained elevated at 2.0 (95% CI 1.1–3.7) after adjusting for age, season and underlying conditions. Conclusion Influenza B virus infections were associated with severe outcomes among hospitalized children. Although death was uncommon, children with B had twice the odds of dying in-hospital compared with those with A virus infection. Disclosures E. J. Anderson, NovaVax: Grant Investigator, Research grant. Pfizer: Grant Investigator, Research grant. AbbVie: Consultant, Consulting fee. MedImmune: Investigator, Research support. PaxVax: Investigator, Research support. Micron: Investigator, Research support. H. K. Talbot, Sanofi Pasteur: Investigator, Research grant. Gilead: Investigator, Research grant. MedImmune: Investigator, Research grant. Vaxinnate: Safety Board, none. Seqirus: Safety Board, none.

2494. Influenza B Hospitalizations Are Associated With Mortality in Children, FluSurv-NET, 2011–2017